CO2 Electroreduction on Carbon-Based Electrodes Functionalized with Molecular Organometallic Complexes—A Mini Review

Heterogeneous electrochemical CO2 reduction has potential advantages with respect to the homogeneous counterpart due to the easier recovery of products and catalysts, the relatively small amounts of catalyst necessary for efficient electrolysis, the longer lifetime of the catalysts, and the elimination of solubility problems. Unfortunately, several disadvantages are also present, including the difficulty of designing the optimized and best-performing catalysts by the appropriate choice of the ligands as well as a larger heterogeneity in the nature of the catalytic site that introduces differences in the mechanistic pathway and in electrogenerated products. The advantages of homogeneous and heterogeneous systems can be preserved by anchoring intact organometallic molecules on the electrode surface with the aim of increasing the dispersion of active components at a molecular level and facilitating the electron transfer to the electrocatalyst. Electrode functionalization can be obtained by non-covalent or covalent interactions and by direct electropolymerization on the electrode surface. A critical overview covering the very recent literature on CO2 electroreduction by intact organometallic complexes attached to the electrode is summarized herein, and particular attention is given to their catalytic performances. We hope this mini review can provide new insights into the development of more efficient CO2 electrocatalysts for real-life applications

Natalizumab in Multiple Sclerosis: Long-Term Management

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCV), particularly after 24 doses and in patients who previously received immunosuppressive drugs. Long-term natalizumab treated, immunosuppressive-pretreated, and JCV antibody-positive patients are asked to rediscuss natalizumab continuation or withdrawal after 24 doses. Until now, there has not been a clear strategy that should be followed to avoid PML risk and in parallel reduce clinical and radiological rebound activity. In this review, we analyzed the results of clinical trials and case reports in relation to the following situations: natalizumab continuation, natalizumab discontinuation followed by full therapeutic suspension or switch to other first or second line MS treatments. Quitting all MS treatment after natalizumab increases MS activity occurrence. The results regarding the therapeutic switch are not homogeneous, so at the moment there are no established guidelines regarding natalizumab treatment after 24 administrations; the choice is currently based on the professional experience of the neurologist, and on patients’ clinical features and preferences